PURPOSE: We report on the in vivo testing of a novel noninvasively adjustable glaucoma drainage device (AGDD), which features an adjustable outflow resistance, and assess the safety and efficiency of this implant.METHODS: Under general anesthesia, the AGDD was implanted on seven white New Zealand rabbits for a duration of 4 months under a scleral flap in a way analogous to the Ex-PRESS device and set in an operationally closed position. The IOP was measured on a regular basis on the operated and control eyes using a rebound tonometer. Once a month the AGDD was adjusted noninvasively from its fully closed to its fully open position and the resulting pressure drop was measured. The contralateral eye was not operated and served as control. After euthanization, the eyes were collected for histology evaluation.RESULTS: The mean preoperative IOP was 11.1 ± 2.4 mm Hg. The IOP was significantly lower for the operated eye (6.8 ± 2 mm Hg) compared to the nonoperated eye (13.1 ± 1.6 mm Hg) during the first 8 days after surgery. When opening the AGDD from its fully closed to fully open position, the IOP dropped significantly from 11.2 ± 2.9 to 4.8 ± 0.9 mm Hg (P < 0.05).CONCLUSIONS: Implanting the AGDD is a safe and uncomplicated surgical procedure. The fluidic resistance was noninvasively adjustable during the postoperative period with the AGDD between its fully closed and fully open positions.
展开▼
机译:目的:我们报告了一种新型的非侵入性可调节青光眼引流装置(AGDD)的体内测试,该装置具有可调节的流出阻力,并评估了这种植入物的安全性和有效性。方法:在全身麻醉下,将AGDD植入7枚在巩膜瓣下以与Ex-PRESS装置类似的方式将新西兰大白兔放置4个月,并置于操作性关闭位置。使用回弹眼压计定期在手术眼和对照眼上测量IOP。每月一次,将AGDD从完全关闭位置完全调整到完全打开位置,并测量由此产生的压降。对侧眼未手术并作为对照。安乐死后,收集眼睛进行组织学评估。结果:术前平均眼压为11.1±2.4 mm Hg。在手术后的前8天,与未手术的眼睛(13.1±1.6 mm Hg)相比,手术的眼睛(6.8±2 mm Hg)的IOP显着降低。当将AGDD从完全关闭位置打开到完全打开位置时,IOP从11.2±2.9毫米汞柱显着下降至4.8±0.9毫米汞柱(P <0.05)。结论:植入AGDD是一种安全且简单的手术程序。在术后期间,AGDD可在完全关闭和完全打开之间进行无创调节。
展开▼